Telehealth Ketamine for Chronic Pain

Ketamine has been used in pain medicine for decades, primarily via IV infusion in clinical settings. The at-home telehealth model for chronic pain is less developed than for psychiatric conditions, but it exists and is expanding. This guide covers the evidence, the appropriate use cases, and how at-home protocols differ from psychiatric applications.

Ketamine's Role in Chronic Pain

Mechanism in Pain

Ketamine's NMDA receptor antagonism is at the heart of its analgesic (pain-relieving) effects. NMDA receptors play a central role in pain sensitization—the process by which the nervous system becomes amplified in its response to pain signals. Conditions characterized by central sensitization (where the pain nervous system itself becomes dysregulated, producing pain in the absence of ongoing tissue damage) may respond particularly well to ketamine.

Pain Conditions with Evidence

Complex Regional Pain Syndrome (CRPS): CRPS is one of the most studied ketamine-responsive pain conditions. Multiple clinical trials and case series have documented significant pain reduction, sometimes including periods of remission, following IV ketamine infusion protocols. CRPS's central sensitization component makes it particularly amenable to NMDA blockade.

Fibromyalgia: Fibromyalgia, characterized by widespread musculoskeletal pain with central sensitization features, has shown response to ketamine in several studies.

Neuropathic Pain: Peripheral and central neuropathic pain conditions—including diabetic neuropathy, post-herpetic neuralgia, and spinal cord injury pain—have evidence for ketamine response.

Migraine and Cluster Headache: Inpatient IV ketamine protocols have been used for refractory migraine and cluster headache.

Post-Surgical Pain: Perioperative IV ketamine is well-established for reducing post-surgical opioid requirements, though this is a clinical rather than at-home application.

At-Home vs. In-Person for Chronic Pain

Why Pain Typically Requires In-Person Treatment

The doses of ketamine used for chronic pain conditions—particularly CRPS—are often substantially higher than psychiatric applications and may require continuous IV infusion over days in an inpatient or intensive outpatient setting. These protocols require continuous medical monitoring and are not compatible with at-home delivery. See our article on when in-person treatment is required for more on this distinction.

The pain applications that are most compatible with at-home delivery are lower-dose oral or sublingual protocols for conditions where moderate analgesic benefit (rather than full pain-blocking doses) is the goal.

When Telehealth Is Appropriate for Pain

At-home telehealth ketamine for chronic pain is most appropriate for:

• Patients who have already been through IV ketamine treatment and are using lower-dose oral/sublingual ketamine for maintenance
• Patients with chronic pain that includes significant depressive or anxiety components, where the psychiatric indication is primary
• Patients using low-dose daily ketamine (a daily low-dose subscription model) as an adjunct to other pain management strategies
• Patients far from specialized pain clinics for whom IV access is practically unavailable and lower-dose oral ketamine provides meaningful relief

Monitoring Requirements for Pain Applications

Chronic pain patients often have more complex medical histories than straightforward psychiatric patients. Blood pressure monitoring is particularly important—many pain patients are also on medications that affect cardiovascular function, and the combination with ketamine's hypertensive effects warrants closer tracking.

At-home monitoring for pain applications should include:

• Pre- and post-session blood pressure and heart rate
• Regular hepatic function monitoring (more frequent than psychiatric applications) if ketamine use is ongoing, given known hepatotoxicity risk with long-term use. Our monitoring requirements guide covers long-term safety tracking
• Regular symptom severity tracking using validated pain scales (VAS, NRS, or condition-specific instruments)

Hepatotoxicity Risk with Long-Term Ketamine Use

A critical safety consideration for chronic pain applications: ketamine can cause hepatotoxicity (liver damage) with prolonged use. This risk is much better documented in recreational heavy ketamine users than in therapeutic settings, but it is real and warrants monitoring in anyone using ketamine regularly over months.

Providers prescribing ketamine for chronic pain should:

• Obtain baseline liver function tests (LFTs) before starting treatment
• Repeat LFTs at regular intervals (typically every 3-6 months)
• Immediately investigate any symptoms of liver dysfunction (right upper quadrant pain, jaundice, fatigue)
• Consider periodic treatment breaks to assess continued necessity

At-home programs for pain applications should have this monitoring integrated as a standard requirement, not an optional add-on.

Finding Telehealth Providers for Pain

Specialized telehealth ketamine pain management is less common than psychiatric telehealth. Options include:

• Pain management specialists with telehealth practices: Some pain medicine physicians have incorporated telehealth into their practice and can prescribe oral ketamine as part of a broader pain management plan
• General telehealth ketamine platforms: Some accept chronic pain as an indication alongside psychiatric conditions. Ask specifically whether they have experience with pain applications and what their monitoring protocols include
• Transitional care from IV programs: Some IV ketamine pain programs offer telehealth follow-up and maintenance prescribing for patients who have completed an initial IV course

When seeking telehealth ketamine for chronic pain, be forthcoming with your full pain history, all pain medications (including opioids), and any prior ketamine treatment.

Opioid Interactions

Many chronic pain patients are on opioid medications. Ketamine and opioids can be used together and are sometimes combined deliberately (ketamine can reduce opioid tolerance and requirements), but the combination requires careful medical oversight. Do not start ketamine without discussing all opioid medications with your prescriber.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches